Therapeutic Response Statement (Sensitivity)

This therapeutic response statement Supports the relationship that FLT3-ITD status confers therapeutic sensitivity to Midostaurin in patients with Acute Myeloid Leukemia.

The Republic of Ireland's Health Service Executive (HSE) has approved midostaurin as a single agent for reimbursement as a treatment option for the maintenance treatment of adult patients with FLT3 mutation positive acute myeloid leukemia (AML) in complete response after completion of induction and consolidation chemotherapy.

This statement is based on a regulatory approval from the Health Service Executive:

Midostaurin is indicated as single agent maintenance therapy for adult patients with FLT3 mutation positive acute myeloid leukaemia (AML) in complete response after completion of induction and consolidation chemotherapy.

Citation

Midostaurin Maintenance Therapy, 2025, version number 2a, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6997/661_v2a_Midostaurin_Maintenance_Therapy.pdf

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2021-10-01	Health Service Executive	Indication approved for reimbursement.